Standards and guidelines for observational studies: quality is in the eye of the beholder.
暂无分享,去创建一个
Sally C Morton | Robert W Dubois | S. Morton | R. Dubois | Jennifer S Graff | Monica R Costlow | J. Graff | Monica Costlow
[1] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.
[2] Scott R. Smith,et al. Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide , 2013 .
[3] John B. Watkins,et al. Standardizing Quality Assessment of Observational Studies for Decision Making in Health Care , 2009, Journal of managed care pharmacy : JMCP.
[4] N. Dreyer,et al. The GRACE Checklist for Rating the Quality of Observational Studies of Comparative Effectiveness: A Tale of Hope and Caution , 2014, Journal of managed care & specialty pharmacy.
[5] M. Halpern,et al. Pharmaceutical technology assessment: perspectives from payers. , 2015, Journal of managed care pharmacy : JMCP.
[6] W. Sauerbrei,et al. STRengthening Analytical Thinking for Observational Studies: the STRATOS initiative , 2014, Statistics in medicine.
[7] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.
[8] Nicholas G. Hall,et al. A Model for Making Project Funding Decisions at the National Cancer Institute , 1992, Oper. Res..
[9] David Atkins,et al. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[10] Michael L. Johnson,et al. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[11] Rachael Fleurence,et al. How the Patient-Centered Outcomes Research Institute is engaging patients and others in shaping its research agenda. , 2013, Health affairs.
[12] D. Meltzer,et al. Toward a Science of Research Prioritization? The Use of Value of Information by Multidisciplinary Stakeholder Groups , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[13] Uwe Siebert,et al. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retr , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[14] A. Holtorf,et al. Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging Markets. , 2012, American health & drug benefits.
[15] H. A. Lingstone,et al. The Delphi Method: Techniques and Applications , 1976 .
[16] C Daniel Mullins,et al. A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[17] Richard E Gliklich,et al. GRACE principles: recognizing high-quality observational studies of comparative effectiveness. , 2010, The American journal of managed care.
[18] R. Brook,et al. Consensus methods: characteristics and guidelines for use. , 1984, American journal of public health.